Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.62 |
| ▸ | CDK1 | P06493 | 10/20 | 0.62 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | BCR | P11274 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034281 | 0.87 | KDR (0.70) | KDRCDK1TBXAS1EGFRKMT2A | |
| SCHEMBL6033704 | 0.87 | KDR (0.69) | KDRCDK1 | |
| SCHEMBL6033750 | 0.86 | KDR (0.70) | KDRCDK1 | |
| SCHEMBL6034280 | 0.85 | CDK1 (0.58) | KDRCDK1TBXAS1EGFRABL1 | |
| SCHEMBL6033825 | 0.85 | SYK (0.55) | KDRCDK1TBXAS1EGFRABL1 | |
| SCHEMBL6033778 | 0.84 | JAK3 (0.59) | KDRCDK1TBXAS1EGFRABL1 | |
| SCHEMBL6033887 | 0.84 | KDR (0.61) | KDRCDK1EGFRKMT2A | |
| SCHEMBL6033273 | 0.84 | KDR (0.61) | KDRCDK1 | |
| SCHEMBL6033811 | 0.83 | KDR (0.74) | KDRCDK1 | |
| SCHEMBL6033765 | 0.82 | KDR (0.76) | KDRCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1187816-B1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMTIED | 2004-09-16 | — | — | US | disclosed |
| US-6579983-B1 | Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase | CELLTECH R&D LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | KDR 3/4885CDK1 58/4885TBXAS1 296/4885 |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | KDR 3/4885CDK1 59/4885TBXAS1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.